There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.

Experts from IPD Analytics discuss payer management of biosimilars in the U.S. market.

In this Q&A from Advisory Board, IPD Analytics' experts discussed what providers need to know about the U.S. biosimilar market.

Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth

IPD Analytics and ICER are collaborating to enhance drug pricing transparency.